Kleo closes Series A round to fund immunotherapy development
Executive Summary
Immunotherapies start-up Kleo Pharmaceuticals Inc. raised an undisclosed amount in its Series A round from Biohaven Pharmaceutical Holding Co. Ltd.; Kleo and Biohaven also entered into a clinical development master services agreement.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice